Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers

Transplant International

Volumn 26, Issue 3, 2013, Pages 281-289

  Ponziani, Francesca Romana ^a   Milani, Alessandro ^a   Gasbarrini, Antonio ^a   Zaccaria, Raffaella ^a   Viganò, Raffaella ^b   Iemmolo, Rosa Maria ^c   Donato, Maria Francesca ^d   Rendina, Maria ^e   Toniutto, Pierluigi ^f   Pasulo, Luisa ^g   Cescon, Matteo ^h   Burra, Patrizia ⁱ   Miglioresi, Lucia ^j   Merli, Manuela ^k   Paolo, Daniele Di ^l   Fagiuoli, Stefano ^g   Pompili, Maurizio ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f UNIVERSITY OF UDINE   (Italy)

^g OSPEDALI RIUNITI   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j San Camillo Teaching Hospital   (Italy)

^k SAPIENZA UNIVERSITY OF ROME   (Italy)

^l UNIVERSITY OF ROME TOR VERGATA   (Italy)

more..

Author keywords

antiviral treatment; genotype 1; hepatitis C recurrence; hepatitis C virus; liver transplant; pegylated interferon; responders; ribavirin; survival

Indexed keywords

ALANINE AMINOTRANSFERASE; CYCLOSPORIN A; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TACROLIMUS; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; CYTOPENIA; DEATH; FEMALE; FOLLOW UP; GENOTYPE; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT INFECTION; RELAPSE; SCORING SYSTEM; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; ITALY; KAPLAN-MEIER ESTIMATE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; RECURRENCE; REGRESSION ANALYSIS; RETREATMENT; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84874116255     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12027     Document Type: Article

References (41)

1. Guillouche P, Feray C,. Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther 2011; 33: 163.
2. Zimmermann T, Hoppe-Lotichius M, Körner A, et al,. The recipient CYP2D6 allele 4-associated poor metabolizer status correlates with an early fibrosis development after liver transplantation. Transpl Int 2011; 24: 1059.
3. Feray C, Shouval D, Samuel D,. Will transplantation of an hepatitis C-infected graft improve the outcome of liver transplantation in HCV patients? Gastroenterology 1999; 117: 263.
4. Berenguer M, Ferrell L, Watson J, et al,. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673.
5. Neumann UP, Berg T, Bahra M, et al,. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830.
6. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M,. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679.
7. Berenguer M, Palau A, Fernandez A, et al,. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006; 12: 1067.
8. Dumortier J, Scoazec JY, Chevallier P, Boillot O,. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669.
9. Selzner N, Renner EL, Selzner M, et al,. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 2009; 88: 1214.
10. Bitetto D, Fabris C, Fornasiere E, et al,. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl Int 2011 Jan; 1: 43.
11. Picciotto FP, Tritto G, Lanza AG, et al,. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459.
12. Gurusamy KS, Tsochatzis E, Xirouchakis E, Burroughs AK, Davidson BR,. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev 2010; 20: CD006803.
13. Ishak K, Baptista A, Bianchi L, et al,. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696.
14. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
15. Berenguer M,. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274.
16. Oton E, Barcena R, Moreno-Planas JM, et al,. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006; 6: 2348.
17. Angelico M, Petrolati A, Lionetti R, et al,. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007; 46: 1009.
18. Lodato F, Berardi S, Gramenzi A, et al,. Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation. Aliment Pharmacol Ther 2008; 28: 450.
19. Jain A, Sharma R, Ryan C, et al,. Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: a single center experience. Clin Transplant 2010; 24: 104.
20. Guido M, Fagiuoli S, Tessari G, et al,. Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut 2002; 50: 697.
21. Shiffman ML,. Treating chronic hepatitis C virus after liver transplantation: balancing the risks against the chance for success. Liver Transpl 2007; 13: 1088.
22. Fernandez I, Meneu JC, Colina F, et al,. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006; 12: 1805.
23. Neumann UP, Biermer M, Eurich D, Neuhaus P, Berg T,. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol 2010; 52: 951.
24. Merli M, Giannelli V, Gentili F, et al,. Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study. Antivir Ther 2011; 16: 879.
25. Toniutto P, Fabris C, Fumo E, et al,. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy. J Gastroenterol Hepatol 2005; 20: 577.
26. EASL. Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245.
27. White DL, Ratziu V, El-Serag HB,. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008; 49: 831.
28. Hui JM, Sud A, Farrell GC, et al,. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003; 125: 1695.
29. Vanni E, Abate ML, Gentilcore E, et al,. Sites and mechanisms ofinsulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology 2009; 50: 697.
30. Gane EJ,. Diabetes mellitus following liver transplantation in patients with hepatitis Cvirus: risks and consequences. Am J Transplant 2012; 12: 531.
31. Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ, et al,. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008; 48: 721.
32. Moucari R, Asselah T, Cazals-Hatem D, et al,. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416.
33. Elgouhari HM, Zein CO, Hanouneh I, Feldstein AE, Zein NN,. Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci 2009; 54: 2699.
34. Biselli M, Andreone P, Gramenzi A, et al,. Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen. Dig Liver Dis 2006; 38: 27.
35. Castells L, Vargas V, Allende H, et al,. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 53.
36. Carrion JA, Navasa M, Garcia-Retortillo M, et al,. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746.
37. Sharma P, Marrero JA, Fontana RJ, et al,. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007; 13: 1100.
38. Zimmerman MA, Trotter JF, Wachs M, et al,. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl Int 2007; 20: 747.
39. Di Bisceglie AM, Shiffman ML, Everson GT, et al,. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 2429.
40. Fukuhara T, Taketomi A, Motomura T, et al,. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 1395: 1577.
41. Charlton MR, Thompson A, Veldt BJ, et al,. IL28B polymorphisms are associated with histological recurrence and treatment responsefollowing liver transplantation in patients with HCV infection. Hepatology 2010; 53: 317.